-+ 0.00%
-+ 0.00%
-+ 0.00%

VVT Med signs exclusive Canadian commercialization deal with CHS for ScleroSafe

PUBT·10/01/2026 21:03:04
VVT Med signs exclusive Canadian commercialization deal with CHS for ScleroSafe
  • VVT Med signed an exclusive Canadian commercialization agreement with CHS for its ScleroSafe venous disease treatment technology.
  • Deal dated Sept. 30, 2026; becomes effective upon Health Canada authorization for ScleroSafe.
  • Initial term set at five years, covering launch preparation, physician education, clinical support, market development, annual growth planning.
  • Partnership adds a Canadian commercial platform as the company expands global distribution for ScleroSafe, which has U.S. FDA 510(k) clearance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VVT Med Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202610011701CANADANWCANADAPR_C1107) on October 01, 2026, and is solely responsible for the information contained therein.